Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202505567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xinda Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji Universi…. Hauptthemen laut MEDLINE: Pyroptosis, Triple Negative Breast Neoplasms, Prodrugs, Immunotherapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai Municipality, Institutional Animal Care and Use Committee of Tongji University.
Abstract (Originalsprache)
Pyroptosis has attracted significant attention for its role in cancer chemotherapy and immunotherapy. However, few drugs have been reported to induce pyroptosis via the Caspase‐3/gasdermin E (GSDME) pathway. Herein, three novel Pt IV prodrugs, MRP , DRP , and HRP are rationally designed by conjugating DNA methyltransferase (DNMT) inhibitor (RG108) and/or histone deacetylase (HDAC) inhibitor (PhB) to the Pt IV center. These prodrugs can be easily reduced to cisplatin ( CDDP ) due to the high glutathione (GSH) levels in tumors, liberating the coordinated ligands. Released RG108 reactivates the GSDME gene and reduces pyroptosis in low GSDME‐expressing tumor cells. Meanwhile, PhB‐induced chromatin loosening enhances CDDP‐DNA binding, which not only increases Caspase‐3 expression, but also upregulates GSDME. HRP demonstrates superior ability to suppress tumor growth and metastasis while reducing systemic toxicity compared with CDDP . By reactivating GSDME and loosening chromatin, HRP effectively boosts tumor cell pyroptosis and exhibits the most pronounced anticancer performance. These findings highlight HRP ’s potential as a therapeutic agent for triple‐negative breast cancer (TNBC) and offer innovative strategies for combining chemotherapy with immunotherapy. To the best of current knowledge, this is the first report of platinum complexes inducing pyroptosis via the Caspase‐3/GSDME pathway in low GSDME‐expressing tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji University, Shanghai, 200092, P. R. China.
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, GBRCE for Functional Molecular Engineering, School of Chemistry, Sun Yat-Se…
ORCID-Profile: Shuo Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai Municipality
- Institutional Animal Care and Use Committee of Tongji University
Zitieren
APA
Yang, X., Xu, C., Zeng, Y., Wang, C., Gao, Y., Ding, J., Chen, S., Pan, Y., Zhang, X., Mao, Z., & Shi, S. (2025). Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202505567
Vancouver
Yang X, Xu C, Zeng Y, Wang C, Gao Y, Ding J, et al. Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer. Advanced Science. 2025. doi:10.1002/advs.202505567
BibTeX
@article{Yang2025,
author = {Yang, Xinda and Xu, Chuansheng and Zeng, Youliang and Wang, Chunhui and Gao, Yan and Ding, Jie and Chen, Sirui and Pan, Yuheng and Zhang, Xin and Mao, Zongwan and Shi, Shuo},
title = {Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202505567}
}
EUVIMED